TELO — Telomir Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1971532 ·
Last close
$0.42
Market Cap
$31.17M
52W High
$1.58
52W Low
$0.40
ADV30
134,684
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -745,196 -705,225 4,641,345 4,515,704 236,746
Jun 2026 0 — -1,764,676 -1,721,528 5,365,904 5,170,286 332,424
Mar 2026 0 — -1,041,336 -990,947 5,789,536 5,560,511 827,310
Dec 2025 0 — -2,134,681 -2,061,193 7,341,361 7,286,670 1,427,991

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,914,453
Investing CF
—
Financing CF
$9,330,416
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.02
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-43,722,538
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-5,873,067
Pretax Income TTM
$-5,875,962
Interest Exp TTM
$2,895
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -10,538,849 -10,413,205 7,341,361 1,427,991 5,913,370 -3,688,188
Dec 2024 0 -12,242,174 -16,532,716 1,324,005 680,968 643,037 -5,070,428
Dec 2023 0 -3,942,048 -13,071,864 4,773,768 1,335,564 3,438,204 -3,859,796
Dec 2022 0 -854,147 -854,147 48,730 986,008 -937,278 -468,661

TTM Snapshot

Revenues TTM
$222,102
NetIncome TTM
$-5,875,962
OpCashFlow TTM
—
Assets (Latest)
$5,365,904
Forward EPS
$-0.28

Peers — same industry

TickerNameMarket CapLastDaily %
RNTX Rein Therapeutics, Inc. $30.75M $0.36 —
NXTC NextCure, Inc. $30.68M $6.70 —
BCTX BriaCell Therapeutics Corp. $30.65M $3.51 —
NSRX Nasus Pharma Ltd $30.57M $2.61 —
ANVS Annovis Bio, Inc. $31.97M $0.74 —

News headlines (Yahoo Finance, 1h cache)

Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
2026-11-18 13:00 · Yahoo
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
2026-10-06 12:00 · Yahoo
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
2026-09-17 12:30 · Yahoo
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
2026-04-24 13:00 · Yahoo
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
2026-03-31 12:00 · Yahoo
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
2026-06-15 12:00 · Yahoo
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
2026-05-20 12:00 · Yahoo
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
2026-09-14 12:00 · Yahoo
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
2026-08-10 12:00 · Yahoo
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
2026-04-14 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.